MLYS MINERALYS THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, MINERALYS THERAPEUTICS INC reported revenue of n/a, net income of −$241M and diluted EPS of −$2.85; for the fiscal year ended December 2025 revenue was n/a.
MLYS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$171M, net income −$155M (margin n/a), EPS −$2.29
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$192M, net income −$178M (margin n/a), EPS −$3.66
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$84.7M, net income −$71.9M (margin n/a), EPS −$1.99
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$31.5M, net income −$29.8M (margin n/a), EPS −$5.77
MLYS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$241M, EPS −$2.85
- Quarter ended Mar 31, 2026: revenue n/a, net income −$39.3M, EPS −$0.47
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$32.2M, EPS −$0.32
- Quarter ended Sep 30, 2025: revenue n/a, net income −$36.9M, EPS −$0.52
- Quarter ended Jun 30, 2025: revenue n/a, net income −$43.3M, EPS −$0.66
- Quarter ended Mar 31, 2025: revenue n/a, net income −$42.2M, EPS −$0.79
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$48.9M, EPS −$1.00
- Quarter ended Sep 30, 2024: revenue n/a, net income −$56.3M, EPS −$1.13
- Quarter ended Jun 30, 2024: revenue n/a, net income −$41.0M, EPS −$0.83
- Quarter ended Mar 31, 2024: revenue n/a, net income −$31.5M, EPS −$0.70
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$24.4M, EPS −$0.60
- Quarter ended Sep 30, 2023: revenue n/a, net income −$22.8M, EPS −$0.57
- Quarter ended Jun 30, 2023: revenue n/a, net income −$12.1M, EPS −$0.31
- Quarter ended Mar 31, 2023: revenue n/a, net income −$12.6M, EPS −$0.51
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$9.07M, EPS −$1.74
- Quarter ended Sep 30, 2022: revenue n/a, net income −$6.68M, EPS −$1.29
- Quarter ended Jun 30, 2022: revenue n/a, net income −$6.48M, EPS −$1.26
- Quarter ended Mar 31, 2022: revenue n/a, net income −$7.57M, EPS −$1.48
MLYS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$142M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$166M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$81.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$29.2M, share buybacks n/a
MLYS balance sheet
- Jun 30, 2026: cash $138M, total assets $668M, total liabilities $117M, shareholders' equity $551M
- Mar 31, 2026: cash $113M, total assets $653M, total liabilities n/a, shareholders' equity $638M
- Dec 31, 2025: cash $173M, total assets $662M, total liabilities $15.1M, shareholders' equity $647M
- Sep 30, 2025: cash $218M, total assets $600M, total liabilities n/a, shareholders' equity $576M
- Jun 30, 2025: cash $102M, total assets $336M, total liabilities n/a, shareholders' equity $314M
- Mar 31, 2025: cash $165M, total assets $355M, total liabilities n/a, shareholders' equity $342M
- Dec 31, 2024: cash $114M, total assets $206M, total liabilities n/a, shareholders' equity $191M
- Sep 30, 2024: cash $97.3M, total assets $268M, total liabilities n/a, shareholders' equity $237M
Is MLYS profitable?
No. MINERALYS THERAPEUTICS INC lost $350M over the last four quarters.
What is MLYS's EPS?
Diluted earnings per share over the last four quarters were −$4.16; −$2.85 in the latest quarter.